Nicole Lamanna, MD

Nicole Lamanna, MD, is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center

Articles by Nicole Lamanna, MD

Unmet Needs and Future Directions in Care in CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan O’Brien, MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

ByNicole Lamanna, MD

January 5th 2023

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Optimizing the Treatment of CLL With Novel Therapies

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD,Deborah M. Stephens, DO

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Novel Therapies for CLL: Sequencing Strategies

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Nicole Lamanna, MD,Catherine C. Coombs, MD

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Treating CLL With Anti-CD20 Antibody Regimens

ByWilliam G. Wierda, MD, PhD,Deborah M. Stephens, DO,Catherine C. Coombs, MD,Nicole Lamanna, MD

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

ByWilliam G. Wierda, MD, PhD,Nicole Lamanna, MD,Catherine C. Coombs, MD,Anthony R. Mato, MD, MSCE,Jacqueline Barrientos, MD, MS

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Ibrutinib Therapy for CLL: Long-Term Data

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Nicole Lamanna, MD

January 24th 2022

Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Therapy for CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Dr. Lamanna Discusses the MURANO Trial in CLL

ByNicole Lamanna, MD

January 2nd 2019

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.

Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL

ByNicole Lamanna, MD

May 15th 2015

Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).

Dr. Lamanna Discusses Lymphocytosis Following CLL Treatment

ByNicole Lamanna, MD

October 3rd 2014

Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new, oral CLL agents.

Nicole Lamanna, MD

Articles by Nicole Lamanna, MD

Unmet Needs and Future Directions in Care in CLL

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

Brief Overview of Chronic Lymphocytic Leukemia

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

Optimizing the Treatment of CLL With Novel Therapies

CAR T-Cell Therapies in CLL

PI3K Inhibitors for CLL

Noncovalent BTK Inhibitors in CLL

Novel Therapies for CLL: Sequencing Strategies

Treating CLL With Anti-CD20 Antibody Regimens

Chemotherapy-Free Regimens as Frontline Therapy in CLL

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

Ibrutinib Therapy for CLL: Long-Term Data

BTK Inhibitors as Frontline Therapy for CLL

Dr. Lamanna Discusses the MURANO Trial in CLL

Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL

Dr. Lamanna Discusses Lymphocytosis Following CLL Treatment

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis